CardieX, an ASX-listed health technology company, announced the acquisition of Silicon Valley-based Blumio, a developer of cardiovascular sensor algorithms and data analysis tools.
CardieX focuses on hypertension, cardiovascular health and other arterial health disorders, while Blumio develops wearable sensor technologies focused on capturing cardiovascular data, including blood pressure measurements.
The acquisition follows a three-year collaboration between the companies, which determined Blumio’s sensor technology to be compatible with CardieX’s ATCOR subsidiary. SphygmoCor Arterial Technology which measures the central aortic pressure waveform.
CardieX will also use Blumio’s assets to enhance its Arty heart health analysis platform in its CONNEQT Pulse and for its CONNEQT Band devices.
“Blumio brings a suite of capabilities in wearable sensor development, signal processing and big data analytics expertise that will benefit both our ATCOR and CONNEQT brands, particularly with respect to ongoing development activities around of our CONNEQT band. This acquisition is a natural extension of our core solutions which provide a comprehensive ecosystem of unique health and wellness features focused on heart health,” CardieX Group CEO Craig Cooper said in a statement.
THE GREAT TREND
CardieX adds Blumio to its group of companies with a number of patented health technologies.
In March, CardieX and AI-powered wearable company Mobvoi announced the launch of their TicWatch GTH Prowhich leverages aspects of ATCOR’s SphygmoCor heart health monitoring technology.